Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Ocular Therapeutix, Inc. (NASDAQ: OCUL).

Full DD Report for OCUL

You must become a subscriber to view this report.


Recent News from (NASDAQ: OCUL)

Increasing Health-Conscious and Sports Vision Treatments Impacting HealthCare Sector
Palm Beach, FL – (May 16, 2018) — An increasingly health-conscious consumer is leading to a wide variety of new opportunities in healthcare, most notably a sudden rise awareness and interest of sports vision therapy. Over 75 million people play sports in the United States and one i...
Source: MarketNewsUpdates.com
Date: May, 16 2018 08:14
Ocular Therapeutix's (OCUL) CEO Antony Mattessich on Q1 2018 Results - Earnings Call Transcript
Ocular Therapeutix, Inc. (OCUL) Q1 2018 Results Earnings Conference Call May 08, 2018 04:30 PM ET Executives Antony Mattessich - President and CEO Donald Notman - CFO Dr. Michael Goldstein - Chief Medical Officer Dr. Dan Bollag - SVP, Regulatory and Quality Kevin Hanley - SVP...
Source: SeekingAlpha
Date: May, 08 2018 19:29
Ocular Therapeutix misses by $0.02, misses on revenue
Ocular Therapeutix (NASDAQ: OCUL ): Q1 EPS of -$0.40 misses by $0.02 . More news on: Ocular Therapeutix, Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 08 2018 16:06
Ocular Therapeutix(TM) Reports First Quarter 2018 Financial Results and Business Update
Targeting DEXTENZA™ NDA Resubmission in the Second Quarter of 2018 Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today a...
Source: Business Wire
Date: May, 08 2018 16:01
Ocular Therapeutix(TM) Announces Treatment of First Patient in Phase 1 Clinical Trial of OTX-TIC (travoprost intracameral implant) for the Treatment of Glaucoma and Ocular Hypertension
Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the treatment of the first patient in a Phase 1, open-label, proof-of-co...
Source: Business Wire
Date: May, 03 2018 08:38
Investor Expectations to Drive Momentum within Quaker Chemical, Ocular Therapeutix, Viad, Ingredion, LivePerson, and Tableau Software - Discovering Underlying Factors of Influence
NEW YORK, May 03, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Quaker Chemical Corporation (NYSE:KWR), Ocular Therapeutix, Inc. (NASDAQ:O...
Source: GlobeNewswire
Date: May, 03 2018 07:45
Key events next week - healthcare
Noteworthy events during the week of April 29 - May 5 for healthcare investors. More news on: EyePoint Pharmaceuticals, Inc., Catalyst Inc., Johnson & Johnson, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: April, 27 2018 15:34
Ocular Therapeutix(TM) to Present Data at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that data from its preclinical research will be highlighted in presentations and ...
Source: Business Wire
Date: April, 27 2018 08:00
Ocular Therapeutix(TM) to Report First Quarter 2018 Financial Results
Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report first quarter ended March 31, 2018 financial results...
Source: Business Wire
Date: April, 26 2018 16:01
Ocular Therapeutix(TM) to Present Data at the American Society of Cataract and Refractive Surgery (ASCRS) Symposium
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced data from its clinical and preclinical research will be highlighted in prese...
Source: Business Wire
Date: April, 09 2018 16:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-236.826.636.906.55308,510
2018-05-226.896.826.976.76276,967
2018-05-216.946.896.9526.81200,877
2018-05-186.946.937.006.80244,151
2018-05-176.946.927.036.82298,926

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-2373,253105,13269.6772Short
2018-05-2252,35485,44161.2750Short
2018-05-2169,804102,23468.2787Short
2018-05-1849,82082,30460.5317Short
2018-05-1767,006106,54662.8893Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on OCUL.


About Ocular Therapeutix, Inc. (NASDAQ: OCUL)

Logo for Ocular Therapeutix, Inc. (NASDAQ: OCUL)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: OCUL)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 08 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 08 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 23 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 23 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 08 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: March, 08 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 08 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 14 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: February, 12 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: February, 07 2018

       

       


      Daily Technical Chart for (NASDAQ: OCUL)

      Daily Technical Chart for (NASDAQ: OCUL)


      Stay tuned for daily updates and more on (NASDAQ: OCUL)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: OCUL)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      OTC Report
      @OTCReporter

       

       


      Disclaimer: OTC Report publishes reports providing information on selected companies. OTC Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. OTC Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in OCUL is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. OTC Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. OTC Report does not own any shares of OCUL and does not buy, sell, or trade any shares of OCUL. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by OTC Report. All rights reserved. Our Full Disclaimer: http://otc.report/disclaimer/